RGS5 expression is a quantitative measure of pericyte coverage of blood vessels

Angiogenesis

Volumn 11, Issue 2, 2008, Pages 141-151

  Mitchell, Tracy S ^a,b   Bradley, John ^a,c   Robinson, Gregory S ^a,d   Shima, David T ^a,e   Ng, Yin Shan ^a,f  

^a OSI Eyetech   (United States)

^b Adnexus Therapeutics   (United States)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d SHIRE   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Pervasis Therapeutics Inc   (United States)

Author keywords

Angiogenesis; Endothelial cell; Mural cell; Pericyte; RGS5; Vascular maturation; Vascular smooth muscle; Vascular stabilization

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CELL INTERACTION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; GENE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; MOUSE; NEOPLASM; NONHUMAN; PERICYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATOR OF G PROTEIN SIGNALING 5 GENE; UPREGULATION;

ANIMALS; ANTIGENS, CD31; APTAMERS, NUCLEOTIDE; CORNEA; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; PERICYTES; PLATELET-DERIVED GROWTH FACTOR; RETINA; RGS PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45049087009     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-007-9085-x     Document Type: Article

References (36)

1. Gerhardt H, Betsholtz C (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314(1):15-23
2. Alon T, Hemo I et al (1995) Vascular endothelial growth-factor acts as a survival factor for newly formed retinal-vessels and has implications for retinopathy of prematurity. Nat Med 1(10):1024-1028
3. Benjamin LE, Golijanin D et al (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103(2):159-165
4. Benjamin LE, Hemo I et al (1998) A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125(9):1591-1598
5. Darland DC, D'Amore PA (1999) Blood vessel maturation: vascular development comes of age. J Clin Invest 103(2):157-158
6. Baluk P, Morikawa S et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801-1815
7. Morikawa S, Baluk P et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985-1000
8. Nehls V, Drenckhahn D (1991) Heterogeneity of microvascular pericytes for smooth-muscle type alpha-actin. J Cell Biol 113(1):147-154
9. Ozerdem U, Grako KA et al (2001) NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 222(2):218-227
10. Nehls V, Denzer K et al (1992) Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 270(3):469-474
11. Berger M, Bergers G et al (2005) Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood 105(3):1094-1101
12. Cho H, Kozasa T et al (2003) Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J 17(1):440-442
13. Lindahl P, Johansson BR et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242-245
14. Goodwin A. M. a. P. A. D. A. (2008) Vessel maturation and perivascular cells. Tumor Angiogenesis: Mechanisms and Cancer Therapy. N. a. D. M. Fusenig, Springer (in press)
15. Bondjers C, Kalen M et al (2003) Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol 162(3):721-729
16. Chen X, Higgins J et al (2004) Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 17(10):1198-1210
17. Furuya M, Nishiyama M et al (2004) Expression of regulator of G protein signaling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203(1):551-558
18. Paik JH, Skoura A et al (2004) Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 18(19):2392-2403
19. Hobson JP, Rosenfeldt HM et al (2001) Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291(5509):1800-1803
20. Rosenfeldt HM, Hobson JP et al (2001) EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J 15(14):2649-2659
21. Rosenfeldt HM, Hobson JP et al (2001) The sphingosine-I-phosphate receptor EDG-I is essential for platelet-derived growth factor-induced cell motility. Biochem Soc Trans 29:836-839
22. Abramsson A, Lindblom P et al (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112(8):1142-1151
23. Armulik A, Abramsson A et al (2005) Endothelial/pericyte interactions. Circ Res 97(6):512-523
24. Heldin CH, Eriksson U et al (2002) New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398(2):284-290
25. Hellstrom M, Kalen M et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14):3047-3055
26. Hirschi KK, Rohovsky SA et al (1998) PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141(3):805-814
27. Bjarnegard M, Enge M et al (2004) Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 131(8):1847-1857
28. Jo N, Mailhos C et al (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168(6):2036-2053
29. Bergers G, Song S et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111(9):1287-1295
30. Green LS, Jellinek D et al (1996) Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35(45):14413-14424
31. Ruckman J, Green LS, Beeson J et al (1998) 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF-165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556-20567
32. Fruttiger M (2007) Development of the retinal vasculature. Angiogenesis 10:77-88
33. Uemura AK, Kusuhara S et al (2006) Angiogenesis in the mouse retina: a model system for experimental manipulation. Exp Cell Res 312(5):676-683
34. Ishida S, Usui T et al (2003) VEGF(164)-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198(3):483-489
35. Usui T, Isbida S et al (2004) VEGF(164(165)) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45(2):368-374
36. von Tell D, Armulik A et al (2006) Pericytes and vascular stability. Exp Cell Res 312(5):623-629